Saturday, October 17, 2026 from 1:45 p.m. to 3:15 p.m. MDT at Salt Palace Convention Center - Ballroom G
Available for 1.50 hours of CPE creditActivity Number: 0217-0000-26-151-L01-PActivity Type: An Application-Based ActivityCritically ill patients frequently develop complex cardiovascular complications that require pharmacists to apply advanced pharmacotherapy principles in dynamic, high-risk settings. This 2-part continuing education activity will focus on cardiac considerations in ICU patients, emphasizing the identification and management of mixed shock states and stress-induced atrial fibrillation in non-cardiac surgery populations. In part 1, participants will examine key pathophysiologic mechanisms and objective clinical data used to differentiate overlapping shock phenotypes and will apply this information to develop patient-specific pharmacologic treatment plans, including the selection and optimization of vasopressors, inotropes, and adjunctive therapies. Part 2 will address the management of stress-induced atrial fibrillation in critically ill patients, with a focus on pharmacologic strategies for acute rate and rhythm control, thoughtful vasopressor selection, and the controversial role of anticoagulation in critical illness/ stress-induced atrial fibrillation in ICU patients using a risk-based framework. Through case-based discussion and practical application, learners will enhance their ability to assess benefit–risk tradeoffs, anticipate medication-related complications, and collaborate effectively within the interprofessional ICU team to optimize hemodynamic stability and patient outcomes.
Learning Objectives1. Determine mixed shock states based on pertinent characteristics and objective data.
2. Compose a pharmacologic treatment plan tailored to the etiology of mixed shock.
3. Describe considerations for initiation of rescue, adjunct and/or oral therapies in patients with mixed shock.
4. Describe the pathophysiology of stress-induced atrial fibrillation.
5. Examine the appropriateness of anticoagulation treatment in the newly diagnosed ICU patient with stress-induced atrial fibrillation using risk stratification.
6. Differentiate between acute pharmacologic therapies for stress-induced atrial fibrillation treatment, considering rate versus rhythm control, and controversial supportive actions (vasopressor selection, dual beta agonism/antagonism, etc).
Pharmacologic Management of Mixed Shock1:45 p.m. to 2:25 p.m. |
Pharmacologic Management of Stress-Induced Atrial Fibrillation in Non-Cardiac ICU Patients2:25 p.m. to 3:05 p.m. |
Panel Q&A Discussion3:05 p.m. to 3:15 p.m. |